ENYO Pharma Announces Two Vonafexor Data Presentations at AASLD The Liver Meeting
Lyon, France. November 3rd, 2021 – ENYO Pharma (ENYO), a private clinical stage biotechnology company developing innovative drug candidates, today announced that two abstracts on Vonafexor were accepted one as oral presentation and one as poster during the upcoming The Liver Meeting® 2021, organized by the American Association for the Study of Liver Diseases (AASLD) on November 12-15, 2021.
Etienne Morel’s talk at ITMO Cell Biology (Aviesan)
Etienne Morel, collaborator of ENYO Pharma, gave a talk describing the results of our collaboration entitled: “Mitochondrial morphodynamics and ER-mitochondria membrane crosstalk in antiviral innate immunity” at “ITMO Cell biology, development and evolution” event organized by Aviesan on October the 6th, 2021.
UBS Biotech Private Company Event
Virtual Event
September 22-23, 2021
Jacky Vonderscher, our CEO, gave a talk during the plenary of the UBS Biotech Private Company Event.
New collaboration with Dr David Durantel’s team
Following the positive proof-of-concept data from 203 study of Vonafexor in combination with pegylated-Interferon (peg-IFN) in viremic patients with chronic hepatitis B (CHB), a new collaboration was initiated with the team of David Durantel at the International Center for Research in Infectiology (CIRI – INSERM U1111, https://ciri.ens-lyon.fr/teams/HepVir).
Annual National Liver Conference – San Antonio
October 1st, 2021
San Antonio, USA
ENYO Pharma will sponsor the 16th Annual National Liver Conference.
https://www.liverconference.com/
Latest Press Release 